To include your compound in the COVID-19 Resource Center, submit it here.

Bydureon exenatide once weekly: QT/QTc study data

A double-blind, U.S. thorough QT (tQT) study in about 75 healthy volunteers showed that 200-500 pg/mL doses of IV exenatide met the primary endpoint by demonstrating no significant QTc interval prolongation,

Read the full 311 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE